New Antibiotic Lolamycin Spares Gut Microbiome While Fighting Infections

The rise of infections caused by Gram-negative pathogens has become a significant public health concern, typically necessitating the use of broad-spectrum antibiotics. These treatments, while effective, often disrupt the gut microbiome, leading to secondary infections and other health complications. Recognizing the urgent need for more selective antibiotics, a new innovative antibiotic, as detailed in a recent study published in Nature, selectively targets Gram-negative bacteria while sparing beneficial gut bacteria. 

Lolamycin, developed by researchers at the University of Illinois Urbana-Champaign, specifically targets the lipoprotein transport system of Gram-negative bacteria. This novel mechanism of action ensures that pathogenic bacteria are effectively eliminated without harming commensal bacteria in the gut. Such selectivity mitigates the risk of secondary infections, such as those caused by Clostridioides difficile, a common and dangerous hospital-associated infection.

The efficacy of lolamycin has been demonstrated across multiple preclinical models. In studies involving over 130 multidrug-resistant clinical isolates, lolamycin showed significant activity. In mouse models of acute pneumonia and septicemia, lolamycin treatment resulted in a 100% survival rate for septicemic mice and a 70% survival rate for those with pneumonia. These promising results underscore the potential of lolamycin to treat severe infections that are resistant to existing antibiotics.

One of the most compelling aspects of lolamycin is its ability to preserve the gut microbiome. Standard antibiotics like amoxicillin and clindamycin often cause dramatic shifts in gut bacterial populations, reducing beneficial microbial groups and increasing susceptibility to secondary infections. In contrast, lolamycin treatment did not cause significant changes in the taxonomic composition of the mouse gut microbiome over a treatment and recovery period. This microbiome-sparing property is vital for reducing the risk of C. difficile colonization and other related complications.

While the discovery of lolamycin is a significant advancement, further research is necessary to bring this antibiotic to clinical use. Extensive testing against a broader range of bacterial strains, detailed toxicology studies, and assessments of resistance development are critical next steps. 

For those interested in learning more about the development and potential of lolamycin, raw sequencing data and analysis scripts have been made available by the researchers. These resources can be accessed at the NCBI Sequence Read Archive and on platforms like GitHub and Zenodo. 


REFERENCES


Muñoz, K.A., Ulrich, R.J., Vasan, A.K. et al. A Gram-negative-selective antibiotic that spares the gut microbiome. Nature (2024). https://doi.org/10.1038/s41586-024-07502-0

A Gram-negative-selective antibiotic that spares the gut microbiome (springer.com)

https://github.com/HPCBio/hergenrother-16S-mouse-2022Sept 

https://zenodo.org/records/10980656

Munoz KA. Development of LolCDE inhibitors as microbiome-sparing gram-negative-selective antibiotics (Doctoral dissertation, University of Illinois at Urbana-Champaign).

Comments

Post a Comment

Popular posts from this blog

Bacteriophage-like behavior of SARS-CoV-2

Image
New study suggests that SARS-CoV-2, the virus that causes COVID-19, exhibits bacteriophage-like behavior, meaning it may not only interact with and provide a reservoir for viral persistence and replication, but also potentially replicate within bacteria in the gut microbiome during both acute and post-COVID phases. This novel mechanism opens new avenues for understanding the complex dynamics between viruses and the human microbiota. Early use of certain antibiotic combinations like amoxicillin/clavulanic acid plus rifaximin or azithromycin plus rifaximin is proposed to target and inhibit viral replication within the gut bacterial populations. The study found that early initiation of these antibiotic therapies (within the first 3 days) resulted in significantly shorter recovery times and higher blood oxygen saturation levels in COVID-19 patients, both vaccinated and unvaccinated. Patients who received early antibiotics were less likely to develop long COVID symptoms according to the st...
Read more

Enhancing Traditional Fermentation with Synthetic Microbial Communities

Image
Traditional fermented foods, such as kimchi, sauerkraut, yogurt, and miso, have long been celebrated for their unique flavors, rich textures, and numerous health benefits. These foods owe their distinct characteristics to complex microbial ecosystems that drive the fermentation process. However, despite their popularity, traditional fermentation techniques face significant challenges that impede their scalability and consistency in the modern food industry.  Key issues with traditional fermentation include: Hazardous Compounds: Certain microbial activities can produce undesirable or even harmful compounds. Off-Odors and Flavors: Uncontrolled fermentation can lead to off-odors and flavors, compromising the sensory qualities of the food. Anti-Nutritional Factors: Some microbial by-products can reduce the nutritional value of the food. Product Stability: Inconsistent microbial activities can result in variable product quality and stability. These challenges stem from the inherent comp...
Read more